Actively Recruiting
Led by Ludwig-Maximilians - University of Munich · Updated on 2025-05-04
352
Participants Needed
3
Research Sites
26 weeks
Total Duration
L
Ludwig-Maximilians - University of Munich
Lead Sponsor
B
Bielefeld University
Collaborating Sponsor
Researchers are evaluating the effect of a patient-centered cooperation between general practitioners (GPs) and community pharmacists on reducing the use of psychotropic, sedative, and anticholinergic potentially inappropriate medications (PSA-PIM) in elderly patients who take multiple medications. This is a multicenter, cluster-randomized trial called the PARTNER study, which compares this intervention to a control group receiving usual care. The study aims to improve medication safety and reduce drug-related risks in older adults with polypharmacy. The intervention group receives an education program for healthcare professionals, including manuals, videos, checklists, and support tools for deprescribing PSA-PIM. It also includes an interprofessional workshop and case conference, a pharmacy visit with medication review and patient empowerment, and a GP practice visit promoting shared decision making. The control group receives only a pharmacy visit with medication review. Both interventions involve collaboration between GPs, pharmacists, and patients to address medication use. Participants are adults aged 65 or older who use at least five medications including one or more PSA-PIM for six months or more. They must be willing to select a regular pharmacy and consent to data sharing between their GP and pharmacy. The study measures reduction in PSA-PIM Drug Burden Index over 6 and 12 months, along with medication exposure, new prescriptions, falls, hospitalizations, cognition, quality of life, insomnia, and adverse drug reactions. Participants will be monitored through medication reviews, questionnaires, and diaries during the study period.
CONDITIONS
Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants receive either intensified and patient-centred cooperation between general practitioners and pharmacists including patient empowerment or extended routine care involving a pharmacy visit with brown bag medication review.
1 to 2 visits including pharmacy and GP practice visits depending on intervention assignment
Total: 3 locations
1
University of Bielefeld
Bielefeld, Germany, 33615
Not Yet Recruiting
2
University Hospital, LMU Munich
Munich, Germany, 80336
Actively Recruiting
3
Witten/Herdecke University
Witten, Germany, 58448
Not Yet Recruiting
T
Tobias Dreischulte, Prof. Dr.
A
Annette Haerdtlein
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Annette Haerdtlein, Kerstin Bernartz, Sophie Peter...
https://pubmed.ncbi.nlm.nih.gov/41522713